Bruce Sizer

Long-Term Outcomes in Patients With Muscle-Invasive Bladder Cancer After Selective Bladder-Preserving Combined-Modality Therapy: A Pooled Analysis of Radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233

The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence

Cancer treatment and survivorship statistics, 2022

Curative Therapy for Bladder Cancer in Routine Clinical Practice: A Population-based Outcomes Study

Viscoelastic properties of human bladder tumours

Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience

Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The immune contexture in cancer prognosis and treatment

A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer

Effects of extracellular matrix viscoelasticity on cellular behaviour

COVID-19: Global radiation oncology’s targeted response for pandemic preparedness

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder

Colorectal cancer

Bladder Preservation Strategies

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends

Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review

Bladder cancer

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

Urothelial carcinoma management in elderly or unfit patients

Recent advances in the diagnosis and treatment of bladder cancer

Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial

Long Noncoding RNA and Cancer: A New Paradigm

Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer

Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder‐preservation therapy for muscle‐invasive bladder cancer

Bladder Cancer

Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data

Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation

Combination therapy in combating cancer

Cancer treatment and survivorship statistics, 2016

Long non‐coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling

Cancer treatment and survivorship statistics, 2019

Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy

Cancer treatment and survivorship statistics, 2014

A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

Results of a prospective randomised control 6 vs 12 trial: Is greater tumour downstaging observed on post treatment MRI if surgery is delayed to 12-weeks versus 6-weeks after completion of neoadjuvant chemoradiotherapy?